Bharat Biotech gets nod for COVID-19 intra-nasal vaccine phase-3 trials

  • | Friday | 28th January, 2022

Hyderabad, Jan. 28 (PTI): Bharat Biotech has received approval from the Drug Controller General of India to conduct phase-3 trials for its COVID-19 intra-nasal vaccine (BBV154), sources in the company said on Friday. The trials would evaluate the nasal vaccine for both the two-dose primary schedule and also to use as booster dose schedule, they said. “BBV154 (nasal covid vaccine) has received approval for phase-3 clinical trials. The trials will evaluate BBV154 nasal vaccine for both the two-dose primary schedule and booster dose schedule,” the sources said. An intra-nasal vaccine would not only be simple to administer but also reduce the use of needles and syringes, among others. It would also impact the overall cost of a vaccination drive, chairman of Bharat Biotech Krishna Ella had said. PTI GDK NVG NVG


If You Like This Story, Support NYOOOZ

NYOOOZ SUPPORTER

NYOOOZ FRIEND

Your support to NYOOOZ will help us to continue create and publish news for and from smaller cities, which also need equal voice as much as citizens living in bigger cities have through mainstream media organizations.


Stay updated with all the Hyderabad Latest News headlines here. For more exclusive & live news updates from all around India, stay connected with NYOOOZ.

Related Articles